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Abstract
Introduction: Bisphosphonates (BPs) can be locally used to improve the
osteogenesis around hydroxyapatite (HA) implants. However, there are almost
no reports discussing the effects of BPs in the bonding state with HA on bone
mesenchymal stromal cells (BMSCs). Clodronate is a BP widely used in clinical
practice. This study was designed to evaluate the effects of clodronate combined
with HA on BMSCs’ multi-directional differentiation.
Material and methods: The HA and clodronate-HA complex were prepared.
BMSCs were isolated from Sprague-Dawley rat bone marrow and then the cells
were cultured with both HA and clodronate-HA. The method of transcriptional
and translational assay (MTT) and multi-directional induction (including
osteogenic, adipogenic, and myogenic differentiation) were used to evaluate
the effect of clodronate-HA on BMSC differentiation. 
Results: Scanning electron microscopy indicated active proliferation of the cells
on clodronate-HA and HA. MTT of BMSCs cultured on clodronate-HA and HA
demonstrated no significant differences between the two groups. BMSCs
differentiated into osteocytes, adipocytes, and myocytes after being cultured
with both clodronate-HA and HA. This indicated that BMSCs still retained multi-
directional capability. The alkaline phosphatase activity of osteogenic induced
BMSCs of both groups had no significant difference. However, there was
a significant difference in total protein found between them. 
Conclusions: The results suggest that clodronate in the bonding state with HA
has no obvious inhibition of the proliferation and activity of BMSCs on the
complex, and there was no evidence of a negative effect on multi-directional
capability of the BMSCs.
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Introduction
Bisphosphonates (BPs), synthetic analogues of pyrophosphate, are
potent inhibitors of bone resorption and have been successfully used with
increasing frequency in the treatment of osteoporosis, fibrous dysplasia,
and osteoarthritis [1-3]. It has also been reported that BPs have positive
effects on bone matrix synthesis [4], and improved bone formation and
mineralization [5]. In fact, the local use of BPs to achieve rapid bone growth
around biomaterials post-surgery has been suggested by various
researchers [6, 7]. Especially, combining BPs with hydroxyapatite (HA)
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would be interesting [8], given that HA is widely
used in orthopedic and oral maxillofacial implants,
and is used to restore hard tissue defects.
Bisphosphonates display a common backbone
structure of P-C-P, where C is carbon and P is
a phosphonate group. Bisphosphonates are known
to be easily combined with HA by chelation. The
two phosphonate groups are both essential for
binding to the calcium ion of HA by chelation and
for the biochemical mechanism. When combined
with HA, the line structure of BPs transfers to a six-
membered ring structure bonding state. It is well
known that the structural change of a chemical
compound could modify its function. However, there
are almost no reports discussing the effects of BPs
combined with HA in the bonding state on bone
mesenchymal stromal cells (BMSCs), especially on
their multi-directional capability. Bone mesenchymal
stromal cells are biologically important cells for
tissue reconstitution, and can differentiate along
multiple lineages such as chondrocytes, osteocytes,
adipocytes, myocytes, and astrocytes [9-11].
Biomaterials combined with BMSCs implanted into
the bone defect could help improve osteogenesis
[12, 13]. Therefore, it is necessary to investigate the
effect of the BP-HA complex on BMSCs in vitro,
before it could be possible to combine both BMSCs
and BPs together to improve HA restoring hard
tissue defects in vivo. 
Clodronate, one of the nitrogen-containing BPs
used widely in clinical practice, has a high affinity
for HA (calcium ions). This study was designed to
compare pure HA with the clodronate-HA complex
to evaluate whether clodronate would have
a negative effect on BMSC proliferation, activities
and multi-directional differentiation.
Material and methods
Material preparation
The preparation of the clodronate-HA complex
(the HA bioceramics for bone scaffolds were
prepared by Sichuan University Research Center for
Nano-Biomaterials, the compressive strength was
40.0 MPa, 10 mm × 10 mm × 1.0 mm) was carried
out using a method previously described [14]. Briefly,
the scaffolds were immersed in a solution of 
4 mg/ml dichloromethylene-BP clodronate disodium
(Shering, Germany) with a pH of 6.5 to 
form clodronate-HA chelate for 48 h at 37°C. 
The specimens were cleaned ultrasonically with
distilled water for 30 min and stored in constant
temperature desiccators (as cleaned specimens).
The release of clodronate in medium was tested by
reverse phase liquid chromatography at 220 nm,
using a Waters 1525 binary HPLC pump (Waters Co.,
USA), a Rheodyne (Cotati, CA, USA) model 7725i
injection valve fitted with a 20 µl loop, and a Waters
2487 dual λ absorbance detector (Waters Co., USA).
The Phenomenex C18 column (USA) was used to
separate the clodronate in the samples at 25°C using
a mixture of acetonitrile and n-amylamine, and the
flow rate was 1 ml/min. Generally, clodronate-HA
specimens were rinsed in 1 ml of an eluting agent
for 24 h, then the solutions were collected, and the
concentration of clodronate was measured. The
procedures were performed once a day over 21 days.
In this study, HA bioceramics without clodronate
(10 mm × 10 mm × 1.0 mm) were sterilized as
a control. 
Isolation and culture of BMSCs 
Bone mesenchymal stromal cells were obtained
from Sprague-Dawley (SD) rats according to the
established methods of our lab [15]. BMSCs were
cultured in an incubator at 37°C, with 5% CO2 for
about 48 h, until cell adherence was observed. 
Bone mesenchymal stromal cells were cultured
on slides and stained according to the manufacturer’s
recommendations with the rabbit anti-mouse
monoclonal antibody of CH3 (SANTA CRUZ, USA;
working dilution was 1 : 100). Positive cells were
detected with Biotin-conjugated goat anti-mouse
IgG (ZhongShan, Beijing, China). CD45 (SANTA
CRUZ, USA) were also stained as above. 
Bone mesenchymal stromal cells were digested
in 0.25% trypsin with 0.02% ethylenediaminetetra  -
acetic acid (EDTA, Sigma, Germany) and blown 
into cell suspension, where density was adjusted
to 2 × 105 cells/ml after cell counting, for pre-
emergency. The materials above were bathed in 
α-modified Eagle's medium (α-MEM) for 24 h, then
in calf serum for more than 4 h before being put
into use. Then, the BMSCs were seeded respectively
on the clodronate-HA and HA discs placed in 
12-well plates and incubated with fresh medium at
37°C with 5% CO2. The culture mediums were
changed three times a week. A phase contrast
microscope (OLYMPUS, Japan) and a scanning
electron microscope (SEM, KYKY-2800) were used
to observe the cell growth on the scaffolds. The cell
proliferation rate on the scaffolds was measured
using the method of transcriptional and
translational assay (MTT) test on day 1, 2, 3, 4, 5, 6,
and 7 after incubation. The absorbance was
measured using a Beckman DU7400 spectro  photo  -
meter at a wavelength of 570 nm.
The MTT data were analyzed by a paired t-test
with SPSS 10.0 (SPSS, Chicago, IL, USA). Differences
at p < 0.05 were statistically significant.
Identification of BMSCs’ multi-directional
differentiation
The cells were cultured in a 12-well plate for 
48 h, then the cells were collected using 0.25%
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trypsin with 0.02% EDTA (Sigma, Germany) and
recultured with specific media for osteogenic,
adipogenic, and myogenic differentiation.
Osteogenic differentiation
According to the method of Conget PA [16], 
low glucose Dulbecco's modified Eagle's 
medium (LG-DMEM, GIBCO, USA; DMEM containing
10% FBS, 100 mM dexamethasone, 10 nM 
β-glycerophosphate, and 0.25 mM L-ascorbic acids)
was added to the plate. The cells were cultured for
2 weeks with media changed twice a week. Induced
cells were collected using 0.25% trypsin with 0.02%
EDTA and recultured on the surface of a cover glass
which contained polylysine in the 12-well plate.
After 2 weeks, staining for alkaline phosphates
(ALP) and calcium with Alizarin Red S (10%, pH 4.2)
was carried out. Cells were collected on day 2, 6,
10, and 14, to measure the ALP and total protein
content. Discs were first washed three times with
phosphate buffer saline (PBS), and then the cells
were collected by using 0.25% trypsin with 0.02%
EDTA and centrifuging. Before determination, the
cell suspension was put into a –80°C freezer for at
least 12 h for the following analysis. 
To measure the ALP level, each sample was
added to the wells of a 24-well plate with 100 µl
paranitrophenyl phosphate (PNP, Sigma, The
Netherlands) solution. The well plate was protected
from light and incubated at 37°C for 1 h. ALP activity
was quantified by absorbance measurements at
405 nm. Finally, the ALP content of cells was
counted through the column diagram.
The total protein concentration of the cells 
on the materials on day 2, 6, 10, and 14 was
determined with a Micro BCA Protein Assay Kit
(Pierce, USA), using bovine serum albumin (BSA),
(Gibco BRL, USA) as a standard.
The data of ALP activity and total protein
concentration were analyzed by a paired t-test with
SPSS 10.0 (SPSS, Chicago, IL, USA). Differences at
p < 0.05 were statistically significant.
Adipogenic differentiation
Adipogenic differentiation was achieved by
adding α-MEM supplemented with 10% fetal bovine
serum (FBS), 10% normal rabbit serum, 10 nM
dexamethasone, 5 µg/mL insulin, and 50 µM
5,8,11,14-eicosatetraynoic acid into plates. A week
later, the induced cells were collected and
recultured as above. Finally, lipid droplets were
stained with Oil Red O (0.3% in isopropanol with
0.4% dextrin) [17].
Myogenic differentiation
BMSCs were first induced into myocardial cells
by adding LG-DMEM (containing 15% [v/v] FBS, 
7.5 µmol/l 5-aza). 24 h later, the medium was
replaced with LG-DMEM which contained 15% (v/v)
FBS and incubated at 37°C with 5% CO2 for 5 days.
After being circulated three times, the induced 
cells were collected and recultured as before.
Immunocytology of desmin (Sigma, USA) and
connexin-43 (Sigma, USA) was used to verify
myocytes.
Results
Clodronate combined with HA
Clodronate combined with the HA by chelation
according to x-ray photoelectron spectrometry (XPS)
and Fourier transform infrared spectroscopy (FT-IR)
analyses (Figure 1 A and B) [14]. In the clodronate
release test, the amount of clodronate was
monitored over 21 days. During the first 6 days
a large amount of clodronate was released; the first
3 days showed a sharp decline (Figure 1C). 
Isolation and culture of bone mesenchymal
stromal cells 
The adherent cells appeared round or polygonal,
growing on the inner wall of the culture flask 24 h
after the initial plating. After replating, the cells
expanded approximately and were fibroblast-like,
appearing polygonal or spindle-shaped with long
processes. The BMSCs’ cell-surface antigen profile
showed a strong positive for SH3 (Figure 2A) and
negative for CD45 (Figure 2B). 
The SEM demonstrated adherence of BMSCs on
clodronate-HA. Morphologically, 7 days after culture,
the cells with several pseudopodia extended to the
surface of both clodronate-HA and HA. The
neighboring cells almost formed a continuous
multilayered conformation (Figures 3A and B).
The MTT assay reflected a parallel growth
tendency of the adherent cells on both materials
and the levels of proliferation were close at the
same time point (Figure 4). According to the
statistical analysis, there was no significant
difference (p > 0.05).
Multi-directional differentiation of bone
mesenchymal stromal cells
Approximately 2 weeks after the osteogenic-
specific induction, the cells grew tightly packed and
spindle-shaped. Then clusters of round calcium-
producing cells formed and calcified nodules could
be seen (Figure 5A). Alizarin Red S also
demonstrated the calcium formation (Figure 5B).
ALP staining showed a strong positive (Figure 5C). 
Figure 6A demonstrates that on day 2, 6, 10, and
14 of incubation, the ALP activity of the osteogenic-
specific induced BMSCs on the clodronate-HA
appeared slightly higher than that on the HA,
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although the difference was not significant 
(p > 0.05). However, Figure 6B shows a significant
difference in protein content between the two
groups (p < 0.05).
One week after adipogenic-specific inductions,
lipid vacuoles were observed in the cells of both
groups. As time passed, the lipid vacuoles
coalesced and eventually filled the cells (Figure 7A).
The lipid vacuoles were stained positively with Oil
Red O (Figure 7B). 
After myogenic-specific inductions, the cells of
both groups showed positive staining of desmin
(Figure 8A) and connexin-43 (Figure 8B). 
Discussion
In the present study, we investigated the effect
of the clodronate-HA complex on BMSC proliferation,
activities and multi-directional differentiation in vitro.
The results demonstrated that clodronate in the
bonding state had no obvious inhibition of
proliferation and multi-directional capability of the
BMSCs, except for a slightly significant difference in
the total protein content. This study might provide
experimental evidence for further studies regarding
the application of BMSCs to improve BP-HA
restoration of hard tissue defects in vivo.
BPs inhibit bone resorption by binding to bone
mineral and also inhibit the function of osteoclasts
that take up the drug. BPs have been developed to
treat several diseases related to bones, teeth, and
calcium metabolism. Clodronate is a kind of BP,
which is a well known potent inhibitor of osteoclast
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Figure 1. XPS and FT-IR analyses. A – XPS spectra of
HA (a), clodronate-HA (b) and 30 s-sputtered
clodronate-HA (c); B – FT-IR spectra of HA (a),
clodronate (b) and clodronate-HA; C – in vitro release
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Figure 2. Immunocytology of BMSCs. A – SH3 positive staining of BMSCs; B – CD45 negative staining of BMSCs
(original magnification of all images 200×) 
A B
Effects of clodronate combined with hydroxyapatite on multi-directional differentiation of mesenchymal stromal cells674 Arch Med Sci 5, October / 2010
activity and is widely used to treat metabolic bone
diseases. In our previous study [14], clodronate was
used to modify the surface of HA. The results of XPS
and FT-IR analyses indicated that clodronate is
immobilized on the surface of HA. It is generally
accepted that the strong chelate binding of the P-
C-P moiety to calcium ions is responsible for the
high affinity of clodronate for HA [18].
Recently, there has been an increased amount
of evidence that BPs also interact with osteoblasts
and BMSCs. Almost all the research on BPs involve
their unbound state, whereas little evidence
involves their bonding state. 
Some studies have indicated that BPs enhance
proliferation and maturation of osteoblasts [19-20]
and inhibit apoptosis [21]. The effects of BPs on
early stages of osteoblastic differentiation are 
not yet well understood, but the effects of BPs
stimulate the formation of osteoblast progenitors
to promote early osteoblastogenesis [22].
Osteoblast progenitors derived mainly from BMSCs
are critically involved in maintaining the dynamic
equilibrium of bone turnover. BMSCs are able to
differentiate along multiple lineages and can be
used as precursor cells for tissue reconstitution or
treatment [23-25]. Bone mesenchymal stromal cells
play a fundamental role in bone regeneration. It has
been reported that BMSCs are also the targets of
BPs [18, 27]. BPs used in treatment promote
differentiation and maturation of pluripotent BMSCs
towards the osteoblastic phenotype by upregulating
bone morphogenetic protein-2 (BMP-2) and core
binding factor α1 (cbfa-1), which are considered to
be the key transcription factors for osteoblastic
differentiation [28].
BPs also upregulate ALP activity and stimulate
fibroblastic colony formation to influence osteogenic
differentiation of BMSCs [29]. ALP is the typical
marker for osteoblast characterization and 
its activity is an early marker of osteogenic
differentiation, with its increased expression
associated with progressive differentiation of
osteoblasts [30]. In this experiment, the ALP activity
of osteogenic induced BMSCs in the two groups
had no significant difference, showing that the
presence of clodronate did not inhibit cell
osteogenic differentiation. There was a significantly
higher protein content observed in the clodronate-
HA group, which was an interesting phenomenon.
Further studies, however, are necessary to clarify
what kinds of proteins were increasing, such as
BMP-2 and cbfa-1, which were reported by previous
studies [28].
Bisphosphonates in an unbound state could
inhibit adipogenic differentiation of BMSCs [32]. 
BP-treated cells showed some changes in
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Figure 4. MTT test of BMSCs cultured on clodronate-
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Figure 3. SEM images of BMSCs on clodronate-HA (A) and SEM images of BMSCs on HA after 7 days of culturing (B)
A B
HA
Clodronate-HA
Xian Liu, Chongyun Bao, Jing Hu, Guozhu Yin, En LuoArch Med Sci 5, October / 2010 675
A
C
B
Figure  5.  Osteogenic differentiation of BMSCs. 
A – inverted phase contrast microscope. Calcified
nodules could be seen; B – alizarin Red S staining of
calcified nodules; C – ALP strong positive staining
(original magnification of all images 200×) 
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Figure 6. ALP viability and total protein of the cells on clodronate-HA and HA on inducing day 2, 6, 10, and 14. 
A – ALP activity; B – total protein content
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phenotype and limitation in their capacity to
produce fat droplets. This limitation could be due
to the activation of extracellular signal-related
kinases (ERK) and/or Jun amino-terminal kinases
(JNK) followed by a decrease in peroxisome
proliferator activated receptor gamma 2 (PPARγ2)
transcription activity. In this study, the capability of
adipogenic differentiation was shown after BMSCs
were cultured with clodronate-HA. There were no
obvious differences in morphology. One possible
reason might lie in the structural change of
clodronate. However, the quantitative analyses,
such as PPARγ2, are out of testing, and further
studies should be pursued. 
In the current study, we compared clodronate-
HA complex with HA. From the results, it could be
concluded that clodronate-HA shows no obvious
inhibition of the proliferation and activities of
BMSCs, and has no evidently negative effect on the
multi-directional capability of BMSCs. 
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